Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, McCammon is a 5-star analyst with an average return of 88.0% and a 64.91% success rate. McCammon covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Celcuity, and Corbus Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Corbus Pharmaceuticals with a $40.78 average price target.
Based on Corbus Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $22.97 million. In comparison, last year the company had a GAAP net loss of $16.98 million
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CRBP in relation to earlier this year. Most recently, in March 2026, Dominic Smethurst, the CMO of CRBP sold 6,097.00 shares for a total of $50,544.13.
